{"id":2773,"date":"2026-07-29T11:08:20","date_gmt":"2026-07-29T11:08:20","guid":{"rendered":"https:\/\/www.iforbes.cz\/?p=2773"},"modified":"2026-07-29T11:08:20","modified_gmt":"2026-07-29T11:08:20","slug":"astrazeneca-zisk-predcil-ocekavani-ale-rozhodujici-zkouska-teprve-prijde","status":"publish","type":"post","link":"https:\/\/www.iforbes.cz\/index.php\/2026\/07\/29\/astrazeneca-zisk-predcil-ocekavani-ale-rozhodujici-zkouska-teprve-prijde\/","title":{"rendered":"AstraZeneca: Zisk p\u0159ed\u010dil o\u010dek\u00e1v\u00e1n\u00ed, ale rozhoduj\u00edc\u00ed zkou\u0161ka teprve p\u0159ijde"},"content":{"rendered":"\n

Finan\u010dn\u00ed sv\u011bt zbyst\u0159il pozornost pot\u00e9, co spole\u010dnost AstraZeneca zve\u0159ejnila sv\u00e9 nejnov\u011bj\u0161\u00ed v\u00fdsledky a nazna\u010dila dal\u0161\u00ed sm\u011b\u0159ov\u00e1n\u00ed firmy. A\u010dkoli prvn\u00ed reakce investor\u016f byla pozitivn\u00ed, pod povrchem z\u016fst\u00e1v\u00e1 \u0159ada ot\u00e1zek, kter\u00e9 mohou ovlivnit budouc\u00ed v\u00fdvoj jej\u00edch akci\u00ed. Pozornost se proto nesoust\u0159ed\u00ed pouze na uplynul\u00e9 \u010dtvrtlet\u00ed, ale p\u0159edev\u0161\u00edm na to, zda tento farmaceutick\u00fd gigant dok\u00e1\u017ee naplnit sv\u00e9 ambici\u00f3zn\u00ed pl\u00e1ny. N\u00e1sleduj\u00edc\u00ed m\u011bs\u00edce mohou uk\u00e1zat, zda je d\u016fv\u011bra trhu skute\u010dn\u011b opr\u00e1vn\u011bn\u00e1. [1]<\/strong><\/p>\n\n\n\n

AstraZeneca PLC je glob\u00e1ln\u00ed biofarmaceutick\u00e1 spole\u010dnost se s\u00eddlem v britsk\u00e9m Cambridge. Spole\u010dnost vznikla v roce 1999 spojen\u00edm \u0161v\u00e9dsk\u00e9 firmy Astra AB a britsk\u00e9 spole\u010dnosti Zeneca Group PLC. Zab\u00fdv\u00e1 se v\u00fdzkumem, v\u00fdvojem, v\u00fdrobou a prodejem l\u00e9k\u016f na p\u0159edpis. Mezi jej\u00ed hlavn\u00ed oblasti p\u016fsobnosti pat\u0159\u00ed onkologie, chronick\u00e1 onemocn\u011bn\u00ed, respira\u010dn\u00ed onemocn\u011bn\u00ed, imunologie a vz\u00e1cn\u00e1 onemocn\u011bn\u00ed. V roce 2025 dos\u00e1hla celkov\u00fdch tr\u017eeb ve v\u00fd\u0161i 58,7 miliardy USD, vlastnila 16 l\u00e9\u010div\u00fdch p\u0159\u00edpravk\u016f s ro\u010dn\u00edmi tr\u017ebami p\u0159esahuj\u00edc\u00edmi 1 miliardu USD a ve sv\u00e9m v\u00fdvojov\u00e9m portfoliu evidovala 197 projekt\u016f. Do roku 2030 pl\u00e1nuje uv\u00e9st na trh nejm\u00e9n\u011b 20 nov\u00fdch l\u00e9k\u016f a zv\u00fd\u0161it ro\u010dn\u00ed tr\u017eby na 80 miliard USD.[1]<\/a>2<\/sup> [2]<\/p>\n\n\n\n

Zisk p\u0159ekonal o\u010dek\u00e1v\u00e1n\u00ed<\/strong><\/p>\n\n\n\n

Spole\u010dnost AstraZeneca dos\u00e1hla ve druh\u00e9m \u010dtvrtlet\u00ed roku 2026 celkov\u00fdch tr\u017eeb ve v\u00fd\u0161i 15,38 miliardy USD, co\u017e p\u0159edstavovalo meziro\u010dn\u00ed r\u016fst o 6 % p\u0159i aktu\u00e1ln\u00edch sm\u011bnn\u00fdch kurzech a o 5 % p\u0159i konstantn\u00edch sm\u011bnn\u00fdch kurzech. V\u00fdsledek se prakticky shodoval s o\u010dek\u00e1v\u00e1n\u00edm analytik\u016f na \u00farovni 15,39 miliardy USD. Mnohem v\u00fdrazn\u011bj\u0161\u00ed p\u0159ekvapen\u00ed p\u0159inesl upraven\u00fd zisk na akcii, kter\u00fd dos\u00e1hl 2,63 USD a p\u0159ekonal konsensus 2,48 USD. Meziro\u010dn\u011b vzrostl o 21 %, p\u0159i\u010dem\u017e po o\u010di\u0161t\u011bn\u00ed o m\u011bnov\u00e9 vlivy vzrostl o 18 %. Upraven\u00fd provozn\u00ed zisk dos\u00e1hl 5,16 miliardy USD a jeho 10% r\u016fst p\u0159ed\u010dil tempo r\u016fstu tr\u017eeb. Hrub\u00e1 mar\u017ee se z\u00e1rove\u0148 zv\u00fd\u0161ila o 1procentn\u00ed bod na 84 %. K r\u016fstu zisku v\u0161ak p\u0159isp\u011bla i ni\u017e\u0161\u00ed da\u0148ov\u00e1 sazba ve v\u00fd\u0161i 15 %, proto nebude snadn\u00e9 udr\u017eet stejn\u00e9 tempo i v dal\u0161\u00edch obdob\u00edch. Za cel\u00e9 prvn\u00ed pololet\u00ed dos\u00e1hla spole\u010dnost AstraZeneca tr\u017eeb ve v\u00fd\u0161i 30,67 miliardy USD a upraven\u00e9ho zisku 5,21 USD na akcii, \u010d\u00edm\u017e potvrdila pokra\u010duj\u00edc\u00ed r\u016fst i p\u0159es tlak na \u0159adu star\u0161\u00edch l\u00e9k\u016f.[2]<\/a> *<\/p>\n\n\n\n

Onkologie z\u016fst\u00e1v\u00e1 hlavn\u00edm motorem<\/strong><\/p>\n\n\n\n

Nejd\u016fle\u017eit\u011bj\u0161\u00edm pil\u00ed\u0159em v\u00fdsledk\u016f z\u016fstala onkologie, kter\u00e1 ve druh\u00e9m \u010dtvrtlet\u00ed dos\u00e1hla tr\u017eeb ve v\u00fd\u0161i 7,33 miliardy USD a tvo\u0159ila p\u0159ibli\u017en\u011b 48 % celkov\u00fdch p\u0159\u00edjm\u016f spole\u010dnosti. Tr\u017eby tohoto segmentu vzrostly p\u0159i konstantn\u00edch sm\u011bnn\u00fdch kurzech o 15 %, \u010d\u00edm\u017e kompenzovaly slab\u0161\u00ed v\u00fdkon \u0159ady star\u0161\u00edch l\u00e9k\u016f. Tr\u017eby z prodeje l\u00e9ku Tagrisso dos\u00e1hly 1,94 miliardy USD a meziro\u010dn\u011b vzrostly o 6 %. V\u00fdrazn\u011bj\u0161\u00ed tempo zaznamenal p\u0159\u00edpravek Imfinzi, jeho\u017e tr\u017eby vysko\u010dily o 27 % na 1,85 miliardy USD. Tr\u017eby p\u0159\u00edpravku Calquence vzrostly o 16 % na 1,02 miliardy USD a tr\u017eby z prodeje p\u0159\u00edpravku Enhertu zv\u00fd\u0161ila spole\u010dnost AstraZeneca o 44 % na 338 milion\u016f USD. Dal\u0161\u00edch 550 milion\u016f USD spole\u010dnost z\u00edskala prost\u0159ednictv\u00edm p\u0159\u00edjm\u016f z alianc\u00ed souvisej\u00edc\u00edch s t\u00edmto l\u00e9kem. Silnou v\u00fdkonnost zaznamenal tak\u00e9 segment vz\u00e1cn\u00fdch onemocn\u011bn\u00ed, jeho\u017e tr\u017eby vzrostly o 8 % na 2,49 miliardy USD. P\u0159\u00edjem z p\u0159\u00edpravku Ultomiris \u010dinil 1,31 miliardy USD a p\u0159\u00edjmy z p\u0159\u00edpravku Strensiq vzrostly o 36 % na 536 milion\u016f USD. R\u016fst spole\u010dnosti tak i nad\u00e1le spo\u010d\u00edv\u00e1 p\u0159edev\u0161\u00edm na nov\u011bj\u0161\u00edch onkologick\u00fdch l\u00e9c\u00edch a portfoliu z\u00edskan\u00e9m akvizic\u00ed spole\u010dnosti Alexion.2<\/sup><\/p>\n\n\n\n

Farxiga a \u010c\u00edna odhaluj\u00ed slab\u00e1 m\u00edsta<\/strong><\/p>\n\n\n\n

Siln\u00fd r\u016fst v onkologii zakryl v\u00fdrazn\u00fd pokles v kardiovaskul\u00e1rn\u00edm, ren\u00e1ln\u00edm a metabolick\u00e9m segmentu, jeho\u017e tr\u017eby p\u0159i konstantn\u00edch sm\u011bnn\u00fdch kurzech klesly o 18 % na 2,77 miliardy USD. Nejv\u011bt\u0161\u00ed negativn\u00ed dopad m\u011bl l\u00e9k Farxiga, jeho\u017e \u010dtvrtletn\u00ed tr\u017eby klesly o 19 % na 1,80 miliardy USD. V \u00fdch Spojen\u00fdch st\u00e1tech jeho tr\u017eby klesly o 48 % na 219 milion\u016f USD pot\u00e9, co na trh vstoupilo n\u011bkolik generick\u00fdch konkurent\u016f. Slab\u0161\u00edm m\u00edstem z\u016fstala i \u010c\u00edna, kter\u00e1 je druh\u00fdm nejv\u011bt\u0161\u00edm trhem spole\u010dnosti. Tr\u017eby v t\u00e9to zemi klesly p\u0159i konstantn\u00edch sm\u011bnn\u00fdch kurzech o 13 % na 1,59 miliardy USD a tvo\u0159ily p\u0159ibli\u017en\u011b 10 % celkov\u00fdch tr\u017eeb. D\u016fvodem byla rostouc\u00ed konkurence generick\u00fdch l\u00e9k\u016f a zm\u011bny ve st\u00e1tn\u00edm syst\u00e9mu hromadn\u00e9ho n\u00e1kupu l\u00e9k\u016f. V\u00fdvoj v ostatn\u00edch regionech byl podstatn\u011b p\u0159\u00edzniv\u011bj\u0161\u00ed. Tr\u017eby ve Spojen\u00fdch st\u00e1tech vzrostly o 6 % na 6,69 miliardy USD, evropsk\u00e9 tr\u017eby se zv\u00fd\u0161ily o 7 % na 3,42 miliardy USD a rozv\u00edjej\u00edc\u00ed se trhy bez \u010c\u00edny zaznamenaly r\u016fst o 11 % na 2,33 miliardy USD.2<\/sup><\/p>\n\n\n\n

R\u016fst vy\u017eaduje st\u00e1le v\u00edce kapit\u00e1lu<\/strong><\/p>\n\n\n\n

Navzdory rostouc\u00edm tr\u017eb\u00e1m se tvorba hotovosti b\u011bhem prvn\u00edho pololet\u00ed oslabila. \u010cist\u00fd p\u0159\u00edliv hotovosti z provozn\u00ed \u010dinnosti klesl ze 7,10 miliardy USD na 6,22 miliardy USD, co\u017e p\u0159edstavuje meziro\u010dn\u00ed pokles o 875 milion\u016f USD. Negativn\u00ed vliv m\u011bla zm\u011bna pracovn\u00edho kapit\u00e1lu ve v\u00fd\u0161i 1,44 miliardy USD a vy\u0161\u0161\u00ed zaplacen\u00e9 dan\u011b, kter\u00e9 vzrostly z 1,55 miliardy USD na 2,05 miliardy USD. Kapit\u00e1lov\u00e9 v\u00fddaje vzrostly o 210 milion\u016f USD na 1,51 miliardy USD, jeliko\u017e spole\u010dnost AstraZeneca pokra\u010dovala v investic\u00edch do v\u00fdrobn\u00edch z\u00e1vod\u016f a technologick\u00e9 infrastruktury. Odliv investic dos\u00e1hl 4,70 miliardy USD a zahrnoval tak\u00e9 platbu ve v\u00fd\u0161i 1,10 miliardy USD spole\u010dnosti CSPC Pharmaceuticals za pr\u00e1va na nov\u00e9 farmaceutick\u00e9 projekty. \u010cist\u00fd dluh se proto od konce roku 2025 zv\u00fd\u0161il o 3,54 miliardy USD na 26,91 miliardy USD. AstraZeneca p\u0159esto zv\u00fd\u0161ila pr\u016fb\u011b\u017enou dividendu o 3 centy na 1,06 USD na akcii. Spole\u010dnost tedy i nad\u00e1le odm\u011b\u0148uje akcion\u00e1\u0159e, z\u00e1rove\u0148 v\u0161ak vyu\u017e\u00edv\u00e1 v\u011bt\u0161\u00ed \u010d\u00e1st sv\u00fdch zdroj\u016f na v\u00fdvoj l\u00e9\u010div, akvizice pr\u00e1v a roz\u0161i\u0159ov\u00e1n\u00ed v\u00fdrobn\u00edch kapacit. 2<\/sup><\/p>\n\n\n\n

Rozhoduj\u00edc\u00edch osmn\u00e1ct m\u011bs\u00edc\u016f<\/strong><\/p>\n\n\n\n

Spole\u010dnost AstraZeneca ponechala v\u00fdhled na rok 2026 beze zm\u011bny. Celkov\u00e9 tr\u017eby by m\u011bly p\u0159i konstantn\u00edch sm\u011bnn\u00fdch kurzech vzr\u016fst o st\u0159edn\u00ed a\u017e vy\u0161\u0161\u00ed jednocifern\u00e9 procento a upraven\u00fd zisk na akcii by m\u011bl zaznamenat n\u00edzk\u00fd dvoucifern\u00fd r\u016fst. Spole\u010dnost z\u00e1rove\u0148 nad\u00e1le po\u010d\u00edt\u00e1 s dosa\u017een\u00edm ro\u010dn\u00edch tr\u017eeb ve v\u00fd\u0161i 80 miliard USD do roku 2030. Spln\u011bn\u00ed tohoto c\u00edle v\u0161ak nebude z\u00e1viset pouze na sou\u010dasn\u00fdch l\u00e9c\u00edch. Spole\u010dnost AstraZeneca o\u010dek\u00e1v\u00e1 v pr\u016fb\u011bhu n\u00e1sleduj\u00edc\u00edch 18 m\u011bs\u00edc\u016f v\u00edce ne\u017e 20 d\u016fle\u017eit\u00fdch v\u00fdsledk\u016f klinick\u00fdch studi\u00ed t\u0159et\u00ed f\u00e1ze, kter\u00e9 mohou potvrdit nebo oslabit hodnotu jej\u00edho v\u00fdvojov\u00e9ho portfolia. Riziko uk\u00e1zalo ned\u00e1vn\u00e9 selh\u00e1n\u00ed studie l\u00e9ku Wainua, po kter\u00e9m spole\u010dnost ztratila p\u0159ibli\u017en\u011b 20 miliard USD ze sv\u00e9 tr\u017en\u00ed hodnoty. Na druhou stranu veden\u00ed zv\u00fd\u0161ilo odhad maxim\u00e1ln\u00edch ro\u010dn\u00edch tr\u017eeb p\u0159ipravovan\u00e9ho respira\u010dn\u00edho l\u00e9ku tozorakimab z v\u00edce ne\u017e 3 miliard USD na v\u00edce ne\u017e 5 miliard USD. Akcie po ozn\u00e1men\u00ed v\u00fdsledk\u016f vzrostly p\u0159ibli\u017en\u011b o 1,7 %, od za\u010d\u00e1tku roku v\u0161ak z\u016fstaly p\u0159ibli\u017en\u011b 7 % v m\u00ednusu. V\u00fdsledky za druh\u00e9 \u010dtvrtlet\u00ed potvrdily s\u00edlu sou\u010dasn\u00e9ho podnik\u00e1n\u00ed, dal\u0161\u00ed v\u00fdvoj akci\u00ed v\u0161ak bude ur\u010dovat p\u0159edev\u0161\u00edm \u00fasp\u011b\u0161nost klinick\u00fdch studi\u00ed a schopnost nov\u00fdch l\u00e9k\u016f nahradit tr\u017eby produkt\u016f, kter\u00e9 p\u0159ich\u00e1zej\u00ed o patentovou ochranu.2[3]<\/a> <\/sup>[3]<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

V\u00fdvoj ceny akci\u00ed spole\u010dnosti AstraZeneca za posledn\u00edch p\u011bt let* TradingView<\/p>\n\n\n\n

Z\u00e1v\u011br<\/strong><\/p>\n\n\n\n

Spole\u010dnost AstraZeneca se dnes nach\u00e1z\u00ed v bod\u011b, kdy jej\u00ed budouc\u00ed r\u016fst nebude z\u00e1viset pouze na siln\u00fdch v\u00fdsledc\u00edch v onkologii, ale p\u0159edev\u0161\u00edm na \u00fasp\u011bchu nov\u00fdch l\u00e9k\u016f a p\u0159ipravovan\u00fdch klinick\u00fdch studi\u00ed. Kombinace rostouc\u00edho portfolia, v\u00edce ne\u017e 20 o\u010dek\u00e1van\u00fdch v\u00fdsledk\u016f studi\u00ed t\u0159et\u00ed f\u00e1ze, expanze v oblasti vz\u00e1cn\u00fdch onemocn\u011bn\u00ed a ambice dos\u00e1hnout tr\u017eeb ve v\u00fd\u0161i 80 miliard USD do roku 2030 vytv\u00e1\u0159\u00ed v\u00fdznamn\u00fd prostor pro dal\u0161\u00ed r\u016fst. Rizikem z\u016fst\u00e1v\u00e1 pokles prodeje star\u0161\u00edch produkt\u016f, slab\u0161\u00ed v\u00fdvoj v \u010c\u00edn\u011b a vysok\u00e1 citlivost akci\u00ed na v\u00fdsledky jednotliv\u00fdch klinick\u00fdch test\u016f. Pokud se spole\u010dnosti AstraZeneca poda\u0159\u00ed \u00fasp\u011b\u0161n\u011b uv\u00e9st na trh nov\u00e9 terapie, nahradit klesaj\u00edc\u00ed tr\u017eby ze star\u0161\u00edch l\u00e9k\u016f a udr\u017eet sou\u010dasn\u00e9 tempo r\u016fstu ziskovosti, mohou b\u00fdt v\u00fdsledky za druh\u00e9 \u010dtvrtlet\u00ed roku 2026 pouze za\u010d\u00e1tkem dal\u0161\u00ed v\u00fdznamn\u00e9 etapy jej\u00edho rozvoje.2<\/sup> [4]<\/p>\n\n\n\n

Adam Austera, analytik <\/strong>Ozios<\/strong><\/a><\/strong><\/p>\n\n\n\n

[1,2,3,4] V\u00fdhledov\u00e1 prohl\u00e1\u0161en\u00ed vych\u00e1zej\u00ed z p\u0159edpoklad\u016f a aktu\u00e1ln\u00edch o\u010dek\u00e1v\u00e1n\u00ed, kter\u00e1 mohou b\u00fdt nep\u0159esn\u00e1, nebo z aktu\u00e1ln\u00edho ekonomick\u00e9ho prost\u0159ed\u00ed, kter\u00e9 se m\u016f\u017ee zm\u011bnit. Takov\u00e1 prohl\u00e1\u0161en\u00ed nejsou z\u00e1rukou budouc\u00ed v\u00fdkonnosti. Zahrnuj\u00ed rizika a dal\u0161\u00ed nejistoty, kter\u00e9 lze jen t\u011b\u017eko p\u0159edv\u00eddat. Skute\u010dn\u00e9 v\u00fdsledky se mohou podstatn\u011b li\u0161it od v\u00fdsledk\u016f vyj\u00e1d\u0159en\u00fdch nebo implikovan\u00fdch v jak\u00fdchkoli v\u00fdhledov\u00fdch prohl\u00e1\u0161en\u00edch.<\/a><\/p>\n\n\n\n

* \u00dadaje t\u00fdkaj\u00edc\u00ed se minulosti nejsou z\u00e1rukou budouc\u00edch v\u00fdnos\u016f. O.Z.I. Online Zone Investment Opportunities (OZIOS<\/a>) je registrovan\u00e1 zna\u010dka spole\u010dnosti APME FX TRADING EUROPE LTD, kypersk\u00e9 investi\u010dn\u00ed spole\u010dnosti (CIF) podl\u00e9haj\u00edc\u00ed dohledu a regulaci Kypersk\u00e9 komise pro cenn\u00e9 pap\u00edry (CySEC) s licenc\u00ed CIF \u010d. 335\/17 a s\u00eddlem na adrese Lophitis Business Center, Office 404, 4. patro, 28 October Ave 249, Limassol 3035, Kypr. Finan\u010dn\u00ed smlouvy o rozd\u00edlu (CFD) jsou slo\u017eit\u00e9 n\u00e1stroje a jsou spojeny s vysok\u00fdm rizikem rychl\u00fdch finan\u010dn\u00edch ztr\u00e1t v d\u016fsledku p\u00e1kov\u00e9ho efektu. U 81,54 % \u00fa\u010dt\u016f retailov\u00fdch investor\u016f doch\u00e1z\u00ed p\u0159i obchodov\u00e1n\u00ed s finan\u010dn\u00edmi kontrakty na rozd\u00edl (CFD) u tohoto poskytovatele k finan\u010dn\u00edm ztr\u00e1t\u00e1m. M\u011bli byste zv\u00e1\u017eit, zda rozum\u00edte tomu, jak finan\u010dn\u00ed kontrakty na rozd\u00edl funguj\u00ed, a zda si m\u016f\u017eete dovolit podstoupit vysok\u00e9 riziko, \u017ee utrp\u00edte finan\u010dn\u00ed ztr\u00e1ty.<\/p>\n\n\n\n

\n\n\n\n

[1]<\/a> https:\/\/en.wikipedia.org\/wiki\/AstraZeneca<\/a><\/p>\n\n\n\n

[2]<\/a> https:\/\/www.astrazeneca.com\/investor-relations\/h1-and-q2-2026-results-event.html<\/a><\/p>\n\n\n\n

[3]<\/a> https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/astrazeneca-beats-second-quarter-profit-expectations-holds-outlook-2026-07-27\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Finan\u010dn\u00ed sv\u011bt zbyst\u0159il pozornost pot\u00e9, co spole\u010dnost AstraZeneca zve\u0159ejnila sv\u00e9 nejnov\u011bj\u0161\u00ed v\u00fdsledky a nazna\u010dila dal\u0161\u00ed sm\u011b\u0159ov\u00e1n\u00ed firmy. A\u010dkoli prvn\u00ed reakce<\/p>\n","protected":false},"author":1,"featured_media":2590,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"colormag_page_container_layout":"default_layout","colormag_page_sidebar_layout":"default_layout"},"categories":[58],"tags":[],"_links":{"self":[{"href":"https:\/\/www.iforbes.cz\/index.php\/wp-json\/wp\/v2\/posts\/2773"}],"collection":[{"href":"https:\/\/www.iforbes.cz\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.iforbes.cz\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.iforbes.cz\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.iforbes.cz\/index.php\/wp-json\/wp\/v2\/comments?post=2773"}],"version-history":[{"count":1,"href":"https:\/\/www.iforbes.cz\/index.php\/wp-json\/wp\/v2\/posts\/2773\/revisions"}],"predecessor-version":[{"id":2775,"href":"https:\/\/www.iforbes.cz\/index.php\/wp-json\/wp\/v2\/posts\/2773\/revisions\/2775"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.iforbes.cz\/index.php\/wp-json\/wp\/v2\/media\/2590"}],"wp:attachment":[{"href":"https:\/\/www.iforbes.cz\/index.php\/wp-json\/wp\/v2\/media?parent=2773"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.iforbes.cz\/index.php\/wp-json\/wp\/v2\/categories?post=2773"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.iforbes.cz\/index.php\/wp-json\/wp\/v2\/tags?post=2773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}